Latest Insider Transactions at Stoke Therapeutics, Inc. (STOK)
This section provides a real-time view of insider transactions for Stoke Therapeutics, Inc. (STOK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Stoke Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Stoke Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,985
+50.0%
|
$0
$0.6 P/Share
|
|
Dec 01
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,700
-62.73%
|
$285,000
$50.85 P/Share
|
|
Dec 01
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+50.0%
|
$11,400
$2.19 P/Share
|
|
Nov 27
2020
|
Edward M. Md Kaye CEO |
SELL
Open market or private sale
|
Direct |
12,152
-32.71%
|
$607,600
$50.0 P/Share
|
|
Nov 25
2020
|
Edward M. Md Kaye CEO |
SELL
Open market or private sale
|
Direct |
12,848
-25.7%
|
$642,400
$50.0 P/Share
|
|
Nov 24
2020
|
Apple Tree Partners Iv, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
375,000
+2.14%
|
$14,625,000
$39.0 P/Share
|
|
Nov 24
2020
|
Seth Loring Harrison |
BUY
Open market or private purchase
|
Indirect |
375,000
+2.14%
|
$14,625,000
$39.0 P/Share
|
|
Nov 23
2020
|
Arthur Tzianabos |
SELL
Open market or private sale
|
Direct |
20,000
-70.66%
|
$920,000
$46.38 P/Share
|
|
Nov 23
2020
|
Arthur Tzianabos |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$40,000
$2.19 P/Share
|
|
Nov 10
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-100.0%
|
$2,250,000
$45.0 P/Share
|
|
Nov 10
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+35.58%
|
$50,000
$1.4 P/Share
|
|
Nov 04
2020
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
33,268
-68.43%
|
$1,363,988
$41.14 P/Share
|
|
Nov 04
2020
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,268
+49.55%
|
$133,072
$4.48 P/Share
|
|
Nov 03
2020
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
1,732
-74.21%
|
$67,548
$39.84 P/Share
|
|
Nov 03
2020
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,732
+42.6%
|
$6,928
$4.48 P/Share
|
|
Nov 02
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,700
-77.75%
|
$210,900
$37.29 P/Share
|
|
Nov 02
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+50.0%
|
$11,400
$2.19 P/Share
|
|
Nov 02
2020
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
35,000
-63.35%
|
$1,295,000
$37.7 P/Share
|
|
Nov 02
2020
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+49.57%
|
$140,000
$4.48 P/Share
|
|
Oct 19
2020
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
32,000
-44.66%
|
$1,216,000
$38.03 P/Share
|
|
Oct 19
2020
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
32,000
+22.07%
|
$32,000
$1.4 P/Share
|
|
Oct 16
2020
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
5,851
-30.24%
|
$234,040
$40.0 P/Share
|
|
Oct 16
2020
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
5,851
+23.22%
|
$0
$0.6 P/Share
|
|
Oct 13
2020
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
1,649
-10.89%
|
$65,960
$40.0 P/Share
|
|
Oct 13
2020
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
1,649
+9.82%
|
$0
$0.6 P/Share
|
|
Oct 01
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,700
-79.82%
|
$193,800
$34.6 P/Share
|
|
Oct 01
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+50.0%
|
$11,400
$2.19 P/Share
|
|
Nov 08
2019
|
Rtw Investments, LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
16,434
-0.46%
|
$460,152
$28.7 P/Share
|
|
Nov 04
2019
|
Rtw Investments, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
104,873
+2.86%
|
$3,041,317
$29.24 P/Share
|
|
Nov 01
2019
|
Rtw Investments, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,598
+0.25%
|
$240,744
$28.61 P/Share
|
|
Oct 31
2019
|
Rtw Investments, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
18,747
+0.54%
|
$524,916
$28.15 P/Share
|
|
Oct 30
2019
|
Rtw Investments, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
41,438
+1.19%
|
$1,160,264
$28.79 P/Share
|
|
Oct 01
2019
|
Rtw Investments, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
31,560
+0.92%
|
$662,760
$21.96 P/Share
|
|
Jun 21
2019
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
671,808
+50.0%
|
-
|
|
Jun 19
2019
|
Rtw Investments, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
555,556
+14.2%
|
$10,000,008
$18.0 P/Share
|
|
Jun 19
2019
|
Rtw Investments, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,799,910
+50.0%
|
-
|